Guizhou Sanli Pharmaceutical Co Ltd (603439.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE1000040B4

Price
10.96 CNY
Market cap
4.50 bn CNY
P/E (2025)
–
P/S (2025)
2.64
Dividend yield
0.55 %
Net margin
2.72 %
Return on equity (ROE)
3.06 %
Return on assets (ROA)
1.62 %

Guizhou Sanli Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue2.14 bn CNY1.70 bn CNY
Gross profit1.49 bn CNY1.19 bn CNY
Operating income326.25 m CNY198.70 m CNY
EBIT339.67 m CNY78.84 m CNY
Net income274.03 m CNY46.25 m CNY

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Guizhou Sanli Pharmaceutical Co Ltd

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonifying, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. In addition, the company trades medicinal herbs. Guizhou Sanli Pharmaceutical Co.,Ltd was founded in 1995 and is based in Anshun, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.